Literature DB >> 14654302

Assessing predictors of drug-induced torsade de pointes.

Luiz Belardinelli1, Charles Antzelevitch, Marc A Vos.   

Abstract

Torsades de pointes (TdP) is a malignant polymorphic ventricular tachyarrhythmia that can be caused by drugs that induce electrophysiological changes. Although the number of drugs known to cause TdP has increased in recent years, there is no cell-based assay, in vitro heart preparation or animal model that predicts the potential of a drug to induce TdP in humans. Nevertheless, certain electrophysiological events are known to be associated with the development of TdP. For example, a drug that prolongs action potential duration, induces early afterdepolarizations and ectopic beats, and increases dispersion of ventricular repolarization is likely to cause TdP. By contrast, a drug that does not induce these changes is unlikely to cause TdP. The exact relationship between these electrophysiological events and the development of TdP has not been defined, but the potential of a drug to elicit these events might predict its pro-arrhythmic risk.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14654302     DOI: 10.1016/j.tips.2003.10.002

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  73 in total

1.  High-precision recording of the action potential in isolated cardiomyocytes using the near-infrared fluorescent dye di-4-ANBDQBS.

Authors:  Mark Warren; Kenneth W Spitzer; Bruce W Steadman; Tyler D Rees; Paul Venable; Tyson Taylor; Junko Shibayama; Ping Yan; Joseph P Wuskell; Leslie M Loew; Alexey V Zaitsev
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-07-02       Impact factor: 4.733

2.  Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias.

Authors:  Tengxian Liu; Barry S Brown; Ying Wu; Charles Antzelevitch; Peter R Kowey; Gan-Xin Yan
Journal:  Heart Rhythm       Date:  2006-04-22       Impact factor: 6.343

3.  A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.

Authors:  C L Lawrence; M H Bridgland-Taylor; C E Pollard; T G Hammond; J-P Valentin
Journal:  Br J Pharmacol       Date:  2006-10-09       Impact factor: 8.739

Review 4.  Modulation of transmural repolarization.

Authors:  Charles Antzelevitch
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

Review 5.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

Authors:  Russell A Wilke; Debbie W Lin; Dan M Roden; Paul B Watkins; David Flockhart; Issam Zineh; Kathleen M Giacomini; Ronald M Krauss
Journal:  Nat Rev Drug Discov       Date:  2007-11       Impact factor: 84.694

6.  Risk stratification [corrected] of Brugada syndrome revisited.

Authors:  Eyal Nof; Charles Antzelevitch
Journal:  Isr Med Assoc J       Date:  2008-06       Impact factor: 0.892

Review 7.  Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes.

Authors:  Charles Antzelevitch
Journal:  Europace       Date:  2007-09       Impact factor: 5.214

Review 8.  Cardiac repolarization. The long and short of it.

Authors:  Charles Antzelevitch
Journal:  Europace       Date:  2005-09       Impact factor: 5.214

Review 9.  Genetics of acquired long QT syndrome.

Authors:  Dan M Roden; Prakash C Viswanathan
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

10.  Electrophysiological and proarrhythmic parameters in transmural canine left-ventricular needle biopsies.

Authors:  S Cora Verduyn; Jérôme G M Jungschleger; Milan Stengl; Roel L H M G Spätjens; Jet D M Beekman; Marc A Vos
Journal:  Pflugers Arch       Date:  2004-10       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.